Spectroscopic and Molecular Docking Studies on Binding Interactions of Camptothecin Drugs with Bovine Serum Albumin

Overview

Journal Sci Rep

Specialty Science

Date 2025 Mar 7

PMID 40055448

Authors

Yuhe Wang

Junfeng Li

Xuanda Li

Bingmiao Gao

Jiao Chen

Yun Song

Affiliations

Soon will be listed here.

Abstract

This study investigates the binding interactions between bovine serum albumin (BSA) and camptothecin (CPT) drugs (camptothecin, 10-hydroxycamptothecin, topotecan, and irinotecan) using UV-Vis spectroscopy, fluorescence spectroscopy, three-dimensional fluorescence spectroscopy, and molecular docking techniques. The fluorescence quenching of BSA by CPT drugs follows a static mechanism, with binding constants (K) ranging from 4.23 × 10 M (CPT) to 101.30 × 10 M (irinotecan), demonstrating significant drug binding selectivity. Thermodynamic analysis reveals distinct interaction mechanisms: topotecan binding is driven by hydrogen bonding (ΔH = - 10.96 kJ·mol) and hydrophobic interactions (ΔS = 0.066 kJ·mol·K), while irinotecan exhibits stronger binding dominated by electrostatic forces (ΔH = - 86.77 kJ·mol) with significant entropy loss (ΔS = - 0.161 kJ·mol·K). Molecular docking confirms preferential binding at Sudlow site I of BSA, with hydrophobic interactions and hydrogen bonding as the primary driving forces. These findings provide a comprehensive understanding of CPT-BSA interactions, offering valuable insights for the design of albumin-based drug delivery systems with optimized pharmacokinetic profiles.

References

Ferreira L, Dos Santos R, Oliva G, Andricopulo A . Molecular docking and structure-based drug design strategies. Molecules. 2015; 20(7):13384-421. PMC: 6332083. DOI: 10.3390/molecules200713384. View

Zhang Y, Xiao C, Li M, Chen J, Ding J, He C . Co-delivery of 10-hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy. Macromol Biosci. 2013; 13(5):584-94. DOI: 10.1002/mabi.201200441. View

Rothenberg M . Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond. Oncologist. 2001; 6(1):66-80. DOI: 10.1634/theoncologist.6-1-66. View

Parodi A, Miao J, Soond S, Rudzinska M, Zamyatnin Jr A . Albumin Nanovectors in Cancer Therapy and Imaging. Biomolecules. 2019; 9(6). PMC: 6627831. DOI: 10.3390/biom9060218. View

Hatefi A, Amsden B . Camptothecin delivery methods. Pharm Res. 2002; 19(10):1389-99. DOI: 10.1023/a:1020427227285. View

He W, Du Y, Zhou W, Yao C, Li X . Redox-sensitive dimeric camptothecin phosphatidylcholines-based liposomes for improved anticancer efficacy. Nanomedicine (Lond). 2019; 14(23):3057-3074. DOI: 10.2217/nnm-2019-0261. View

Casado A, Sagrista M, Mora M . Formulation and in vitro characterization of thermosensitive liposomes for the delivery of irinotecan. J Pharm Sci. 2014; 103(10):3127-38. DOI: 10.1002/jps.24097. View

Tan H, Wang G, Li J, Meng G, Liu Z, Dong M . Synthesis of novel 10-hydroxycamptothecin derivatives utilizing topotecan hydrochloride as ortho-quinonemethide precursor. Bioorg Med Chem. 2014; 23(1):118-25. DOI: 10.1016/j.bmc.2014.11.020. View

Li X, Ni T . Probing the binding mechanisms of α-tocopherol to trypsin and pepsin using isothermal titration calorimetry, spectroscopic, and molecular modeling methods. J Biol Phys. 2016; 42(3):415-34. PMC: 4942422. DOI: 10.1007/s10867-016-9415-6. View

10.

Macii F, Biver T . Spectrofluorimetric analysis of the binding of a target molecule to serum albumin: tricky aspects and tips. J Inorg Biochem. 2020; 216:111305. DOI: 10.1016/j.jinorgbio.2020.111305. View

11.

Fan L, Zhang Y, Wang F, Yang Q, Tan J, Grifantini R . Multifunctional all-in-one drug delivery systems for tumor targeting and sequential release of three different anti-tumor drugs. Biomaterials. 2015; 76:399-407. DOI: 10.1016/j.biomaterials.2015.10.069. View

12.

Siddiqui S, Ameen F, Kausar T, Nayeem S, Rehman S, Tabish M . Biophysical insight into the binding mechanism of doxofylline to bovine serum albumin: An in vitro and in silico approach. Spectrochim Acta A Mol Biomol Spectrosc. 2020; 249:119296. DOI: 10.1016/j.saa.2020.119296. View

13.

Fernandez-Sainz J, Pacheco-Linan P, Granadino-Roldan J, Bravo I, Garzon A, Rubio-Martinez J . Binding of the anticancer drug BI-2536 to human serum albumin. A spectroscopic and theoretical study. J Photochem Photobiol B. 2017; 172:77-87. DOI: 10.1016/j.jphotobiol.2017.05.016. View

14.

Chiara S, Nobile M, Tomasello L, Acquati M, Taveggia P, Murolo C . Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer. Anticancer Res. 2005; 25(2B):1391-6. View

15.

Hama M, Ishima Y, Chuang V, Ando H, Shimizu T, Ishida T . Evidence for Delivery of Abraxane via a Denatured-Albumin Transport System. ACS Appl Mater Interfaces. 2021; 13(17):19736-19744. DOI: 10.1021/acsami.1c03065. View

16.

Rehman S, Sarwar T, Husain M, Ishqi H, Tabish M . Studying non-covalent drug-DNA interactions. Arch Biochem Biophys. 2015; 576:49-60. DOI: 10.1016/j.abb.2015.03.024. View

17.

Solanki R, Rostamabadi H, Patel S, Jafari S . Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: A critical review. Int J Biol Macromol. 2021; 193(Pt A):528-540. DOI: 10.1016/j.ijbiomac.2021.10.040. View

18.

Yang M, Li J, Gu P, Fan X . The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Bioact Mater. 2021; 6(7):1973-1987. PMC: 7773537. DOI: 10.1016/j.bioactmat.2020.12.010. View

19.

Wang X, Zhuang Y, Wang Y, Jiang M, Yao L . The recent developments of camptothecin and its derivatives as potential anti-tumor agents. Eur J Med Chem. 2023; 260:115710. DOI: 10.1016/j.ejmech.2023.115710. View

20.

Khaiwa N, Maarouf N, Darwish M, Alhamad D, Sebastian A, Hamad M . Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise. Eur J Med Chem. 2021; 223:113639. DOI: 10.1016/j.ejmech.2021.113639. View